NCT01825122已完成2 期
Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction
Invion, Inc.4 个研究点 分布在 1 个国家目标入组 155 人开始时间: 2014年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 155
- 试验地点
- 4
- 主要终点
- Change From Baseline in the Average Number of Cigarettes Smoked Per Day
研究概览
简要总结
To test the hypothesis that treatment with the inverse agonist nadolol will improve smoking cessation in patients with chronic cough associated with long-term smoking, with or without airflow obstruction, including those with established chronic obstructive pulmonary disease (COPD) (chronic bronchitis dominant) or non-obstructive chronic bronchitis (NCB), compared to placebo and standard of care, while undergoing a validated smoking cessation program.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Potential study participants will be referred from approved smoking cessation programs or be willing to enter a smoking cessation program administered by the participating sites. Individuals who meet all of the following criteria at Visit 1 are eligible for enrollment as study participants:
- •Active cigarette-smoking males and females between the ages of 18-70 with chronic cough associated with long-term smoking, with or without airflow obstruction, including Non-obstructive chronic bronchitis (NCB) or physician-diagnosed COPD (chronic bronchitis dominant), as defined by the American Thoracic Society.
- •Committed desire to quit smoking in conjunction with participation in an approved smoking cessation program administered by the participating sites. Enrollment in the smoking cessation program must take place prior to Visit 3 (third dose escalation visit).
- •Diagnosis of COPD (chronic bronchitis dominant) or NCB, or presenting with chronic cough associated with long-term smoking.
- •Pre-bronchodilator FEV1 greater than 55% of predicted
- •Baseline blood pressure ≥ 110/65mm Hg
- •Baseline heart rate ≥ 60 beats/min.
- •Smoking at least 10 cigarettes per day prior to participation in the approved smoking cessation program.
- •Self-reported prior failure(s) to quit smoking during participation in a smoking cessation program.
- •Able to complete diary cards and comply with study procedures.
- •Females of childbearing age may participate only if they have a negative pregnancy test, are non-lactating, and agree to practice an adequate birth control method (abstinence, combination barrier and spermicide, or hormonal) for the duration of the study.
排除标准
- •Subjects who meet ANY of the following criteria are not eligible for enrollment:
- •Diagnosis of asthma, cystic fibrosis, or PiZZ emphysema
- •Inability or unwillingness to give written informed consent
- •History of upper/lower respiratory tract infection, COPD exacerbation requiring systemic steroids, antibiotics, and or ER visit or urgent care within 6 weeks of Visit 1
- •History of adverse reaction or allergy to nadolol
- •History of neurological, hepatic, renal, or other medical conditions that may interfere with the interpretation of data or the patient's participation in the study or may increase safety concerns
- •History of cardiovascular diseases including uncontrolled hypertension (BP >160/100), ischemic heart disease, congestive heart failure (NYHA III or IV), valvular heart disease or cardiomyopathy
- •Known allergy or sensitivity to atropine or ipratropium bromide
- •Documented or self-reported current history of alcoholism or drug abuse
- •Participation in another research trial within 30 days of starting this trial
- •Unwillingness or inability to comply with study procedures
- •Inability to swallow the study medication
- •Pregnant or nursing
- •Current use of any OTC remedies containing pseudoephedrine, ephedrine-based or containing dietary or herbal supplements.
- •Scheduled for surgery requiring general anaesthesia
- •Referred for smoking cessation without serious commitment to quit
研究组 & 干预措施
Placebo
Placebo Comparator
placebo
干预措施: Placebo (Drug)
Active, nadolol
Experimental
Active
干预措施: Nadolol (Drug)
结局指标
主要结局
Change From Baseline in the Average Number of Cigarettes Smoked Per Day
时间窗: Baseline to end of treatment, up to 15 weeks
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
Unknown
2 期
Efficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol, in Mild AsthmaMild Persistent Asthma, UncomplicatedNCT01804218Invion, Inc.60
终止
2 期
Baclofen Effects on Smoking Urge and WithdrawalNicotine Use DisorderNicotine DependenceSmokingTobacco Use DisorderNCT00257894VA Office of Research and Development41
已完成
不适用
Novel Medication as a Potential Smoking Cessation AidTobacco Use DisorderNCT02265367University of Minnesota56
已完成
2 期
Efficacy of Naltrexone in Women's Smoking CessationSmokingSmoking CessationNCT00271024University of Chicago333
已完成
4 期
Distribution of Bupropion and Varenicline to Increase Smoking Cessation AttemptsTobacco Use DisorderSmokingSmoking CessationNCT01023659Centre for Addiction and Mental Health893